Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials

Journal of Sexual Medicine

Volumn 13, Issue 7, 2016, Pages 1029-1046

  Trost, Landon W ^a,b   Mulhall, John P ^b  

^a MAYO CLINIC   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Androgen; Erectile Dysfunction; Hypogonadism; Libido; Measure; Steroid

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ESTRADIOL; STEROID 5ALPHA REDUCTASE; TESTOSTERONE;

AGING; BONE DENSITY; CIRCADIAN RHYTHM; COMORBIDITY; DAILY LIFE ACTIVITY; DISEASE ACTIVITY; EQUILIBRIUM DIALYSIS; ETHNICITY; GEOGRAPHIC DISTRIBUTION; HEREDITY; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; HYPOGONADISM; IMMUNOASSAY; LIFESTYLE; MASS SPECTROMETRY; MEDICAL DOCUMENTATION; METHODOLOGY; PHYSIOLOGICAL PROCESS; POPULATION DISTRIBUTION; PRIORITY JOURNAL; QUESTIONNAIRE; RADIOIMMUNOASSAY; REVIEW; BLOOD; MALE; PROSPECTIVE STUDY; REFERENCE VALUE; RETROSPECTIVE STUDY;

HUMANS; HYPOGONADISM; MALE; PROSPECTIVE STUDIES; REFERENCE VALUES; RESEARCH DESIGN; RETROSPECTIVE STUDIES; SURVEYS AND QUESTIONNAIRES; TESTOSTERONE;

EID: 84974653290     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1016/j.jsxm.2016.04.068     Document Type: Review

References (144)

1. Bhasin S., Cunningham G.R., Hayes F.J., et al. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010, 95:2536-2559.
2. Araujo A.B., Esche G.R., Kupelian V., et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007, 92:4241-4247.
3. Liu C.C., Wu W.J., Lee Y.C., et al. The prevalence of and risk factors for androgen deficiency in aging Taiwanese men. J Sex Med 2009, 6:936-946.
4. Wu F.C., Tajar A., Beynon J.M., et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010, 363:123-135.
5. Spitzer M., Huang G., Basaria S., et al. Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol 2013, 9:414-424.
6. Baillargeon J., Urban R.J., Ottenbacher K.J., et al. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med 2013, 173:1465-1466.
7. Handelsman D.J. Global trends in testosterone prescribing, 2000-2011: Expanding the spectrum of prescription drug misuse. Med J Aust 2013, 199:548-551.
8. Hayes F.J., DeCruz S., Seminara S.B., et al. Differential regulation of gonadotropin secretion by testosterone in the human male: Absence of a negative feedback effect of testosterone on follicle-stimulating hormone secretion. J Clin Endocrinol Metab 2001, 86:53-58.
9. Schnorr J.A., Bray M.J., Veldhuis J.D. Aromatization mediates testosterone's short-term feedback restraint of 24-hour endogenously driven and acute exogenous gonadotropin-releasing hormone-stimulated luteinizing hormone and follicle-stimulating hormone secretion in young men. J Clin Endocrinol Metab 2001, 86:2600-2606.
10. Mazer N.A. A novel spreadsheet method for calculating the free serum concentrations of testosterone, dihydrotestosterone, estradiol, estrone and cortisol: With illustrative examples from male and female populations. Steroids 2009, 74:512-519.
11. Carani C., Qin K., Simoni M., et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997, 337:91-95.
12. Pentikainen V., Erkkila K., Suomalainen L., et al. Estradiol acts as a germ cell survival factor in the human testis in vitro. J Clin Endocrinol Metab 2000, 85:2057-2067.
13. Melcangi R.C., Magnaghi V., Martini L. Steroid metabolism and effects in central and peripheral glial cells. J Neurobiol 1999, 40:471-483.
14. Andersson S., Russell D.W. Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. Proc Natl Acad Sci U S A 1990, 87:3640-3644.
15. Schwartz J.I., Tanaka W.K., Wang D.Z., et al. MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen. J Clin Endocrinol Metab 1997, 82:1373-1377.
16. Thigpen A.E., Silver R.I., Guileyardo J.M., et al. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 1993, 92:903-910.
17. Kim K.S., Liu W., Cunha G.R., et al. Expression of the androgen receptor and 5 alpha-reductase type 2 in the developing human fetal penis and urethra. Cell Tissue Res 2002, 307:145-153.
18. Amory J.K., Wang C., Swerdloff R.S., et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab 2007, 92:1659-1665.
19. Traish A.M., Goldstein I., Kim N.N. Testosterone and erectile function: From basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction. Eur Urol 2007, 52:54-70.
20. Traish A.M., Guay A.T. Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med 2006, 3:382-404.
21. Yassin A.A., Saad F., Traish A. Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: A series of case reports. J Sex Med 2006, 3:727-735.
22. Agis-Balboa R.C., Pinna G., Zhubi A., et al. Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis. Proc Natl Acad Sci U S A 2006, 103:14602-14607.
23. Majewska M.D., Harrison N.L., Schwartz R.D., et al. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 1986, 232:1004-1007.
24. Borst S.E., Yarrow J.F., Conover C.F., et al. Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: A randomized, controlled trial. Am J Physiol Endocrinol Metab 2014, 306:E433-E442.
25. Bang H.J., Yang Y.J., Lho D.S., et al. Comparative studies on level of androgens in hair and plasma with premature male-pattern baldness. J Dermatol Sci 2004, 34:11-16.
26. Zhang M.G., Wu W., Zhang C.M., et al. Effects of oral finasteride on erectile function in a rat model. J Sex Med 2012, 9:1328-1336.
27. Pinsky M.R., Gur S., Tracey A.J., et al. The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function. J Sex Med 2011, 8:3066-3074.
28. Imperato-McGinley J., Guerrero L., Gautier T., et al. Steroid 5alpha-reductase deficiency in man: An inherited form of male pseudohermaphroditism. Science 1974, 186:1213-1215.
29. Katz M.D., Kligman I., Cai L.Q., et al. Paternity by intrauterine insemination with sperm from a man with 5alpha-reductase-2 deficiency. N Engl J Med 1997, 336:994-997.
30. Ivarsson S.A., Nielsen M.D., Lindberg T. Male pseudohermaphroditism due to 5 alpha-reductase deficiency in a Swedish family. Eur J Pediatr 1988, 147:532-535.
31. Mifsud A., Sim C.K., Boettger-Tong H., et al. Trinucleotide (CAG) repeat polymorphisms in the androgen receptor gene: Molecular markers of risk for male infertility. Fertil Steril 2001, 75:275-281.
32. Zitzmann M., Brune M., Kornmann B., et al. The CAG repeat polymorphism in the androgen receptor gene affects bone density and bone metabolism in healthy males. Clin Endocrinol 2001, 55:649-657.
33. Schneider G., Nienhaus K., Gromoll J., et al. Sex hormone levels, genetic androgen receptor polymorphism, and anxiety in >/=50-year-old males. J Sex Med 2011, 8:3452-3464.
34. Dhiman P., Bhansali A., Prasad R., et al. Predictors of pilosebaceous unit responsiveness to testosterone therapy in patients with hypogonadotrophic hypogonadism. Andrologia 2011, 43:422-427.
35. Muehlenbein M.P., Hirschtick J.L., Bonner J.Z., et al. Toward quantifying the usage costs of human immunity: Altered metabolic rates and hormone levels during acute immune activation in men. Am J Hum Biol 2010, 22:546-556.
36. Travison T.G., Araujo A.B., Kupelian V., et al. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab 2007, 92:549-555.
37. Yeap B.B., Alfonso H., Chubb S.A., et al. Reference ranges and determinants of testosterone, dihydrotestosterone, and estradiol levels measured using liquid chromatography-tandem mass spectrometry in a population-based cohort of older men. J Clin Endocrinol Metab 2012, 97:4030-4039.
38. Bhasin S., Pencina M., Jasuja G.K., et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab 2011, 96:2430-2439.
39. Feldman H.A., Longcope C., Derby C.A., et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: Longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002, 87:589-598.
40. Ferrini R.L., Barrett-Connor E. Sex hormones and age: A cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol 1998, 147:750-754.
41. Harman S.M., Metter E.J., Tobin J.D., et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001, 86:724-731.
42. Shi Z., Araujo A.B., Martin S., et al. Longitudinal changes in testosterone over five years in community-dwelling men. J Clin Endocrinol Metab 2013, 98:3289-3297.
43. Sartorius G., Spasevska S., Idan A., et al. Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: The healthy man study. Clin Endocrinol 2012, 77:755-763.
44. Wang C., Catlin D.H., Demers L.M., et al. Measurement of total serum testosterone in adult men: Comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 2004, 89:534-543.
45. Vesper H.W., Bhasin S., Wang C., et al. Interlaboratory comparison study of serum total testosterone [corrected] measurements performed by mass spectrometry methods. Steroids 2009, 74:498-503.
46. Steinberger E., Ayala C., Hsi B., et al. Utilization of commercial laboratory results in management of hyperandrogenism in women. Endocr Pract 1998, 4:1-10.
47. Sartorius G., Ly L.P., Sikaris K., et al. Predictive accuracy and sources of variability in calculated free testosterone estimates. Ann Clin Biochem 2009, 46:137-143.
48. Brambilla D.J., Matsumoto A.M., Araujo A.B., et al. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab 2009, 94:907-913.
49. Panizzon M.S., Hauger R., Jacobson K.C., et al. Genetic and environmental influences of daily and intra-individual variation in testosterone levels in middle-aged men. Psychoneuroendocrinology 2013, 38:2163-2172.
50. Bogaert V., Taes Y., Konings P., et al. Heritability of blood concentrations of sex-steroids in relation to body composition in young adult male siblings. Clin Endocrinol 2008, 69:129-135.
51. Kuijper E.A., Lambalk C.B., Boomsma D.I., et al. Heritability of reproductive hormones in adult male twins. Hum Reprod 2007, 22:2153-2159.
52. Ring H.Z., Lessov C.N., Reed T., et al. Heritability of plasma sex hormones and hormone binding globulin in adult male twins. J Clin Endocrinol Metab 2005, 90:3653-3658.
53. Orwoll E.S., Nielson C.M., Labrie F., et al. Evidence for geographical and racial variation in serum sex steroid levels in older men. J Clin Endocrinol Metab 2010, 95:E151-E160.
54. Brambilla D.J., O'Donnell A.B., Matsumoto A.M., et al. Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clin Endocrinol 2007, 67:853-862.
55. Morley J.E., Patrick P., Perry H.M. Evaluation of assays available to measure free testosterone. Metabolism 2002, 51:554-559.
56. Corona G., Rastrelli G., Monami M., et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: A systematic review and meta-analysis. Eur J Endocrinol 2013, 168:829-843.
57. Khoo J., Tian H.H., Tan B., et al. Comparing effects of low- and high-volume moderate-intensity exercise on sexual function and testosterone in obese men. J Sex Med 2013, 10:1823-1832.
58. Cadore E.L., Lhullier F.L., Alberton C.L., et al. Salivary hormonal responses to different water-based exercise protocols in young and elderly men. J Strength Cond Res 2009, 23:2695-2701.
59. Ahtiainen J.P., Pakarinen A., Kraemer W.J., et al. Acute hormonal responses to heavy resistance exercise in strength athletes versus nonathletes. Can J Appl Physiol 2004, 29:527-543.
60. Cadore E.L., Lhullier F.L., Brentano M.A., et al. Hormonal responses to resistance exercise in long-term trained and untrained middle-aged men. J Strength Cond Res 2008, 22:1617-1624.
61. Svartberg J., Midtby M., Bonaa K.H., et al. The associations of age, lifestyle factors and chronic disease with testosterone in men: The Tromso Study. Eur J Endocrinol 2003, 149:145-152.
62. Ponholzer A., Plas E., Schatzl G., et al. Relationship between testosterone serum levels and lifestyle in aging men. Aging Male 2005, 8:190-193.
63. Field A.E., Colditz G.A., Willett W.C., et al. The relation of smoking, age, relative weight, and dietary intake to serum adrenal steroids, sex hormones, and sex hormone-binding globulin in middle-aged men. J Clin Endocrinol Metab 1994, 79:1310-1316.
64. Jeng H.A., Chen Y.L., Kantaria K.N. Association of cigarette smoking with reproductive hormone levels and semen quality in healthy adult men in Taiwan. J Environ Sci Health A Tox Hazard Subst Environ Eng 2014, 49:262-268.
65. Halmenschlager G., Rossetto S., Lara G.M., et al. Evaluation of the effects of cigarette smoking on testosterone levels in adult men. J Sex Med 2009, 6:1763-1772.
66. Valero-Politi J., Fuentes-Arderiu X. Annual rhythmic variations of follitropin, lutropin, testosterone and sex-hormone-binding globulin in men. Clin Chim Acta 1998, 271:57-71.
67. Ruhayel Y., Malm G., Haugen T.B., et al. Seasonal variation in serum concentrations of reproductive hormones and urinary excretion of 6-sulfatoxymelatonin in men living north and south of the Arctic Circle: A longitudinal study. Clin Endocrinol 2007, 67:85-92.
68. Nicolau G.Y., Lakatua D., Sackett-Lundeen L., et al. Circadian and circannual rhythms of hormonal variables in elderly men and women. Chronobiol Int 1984, 1:301-319.
69. Brambilla D.J., O'Donnell A.B., Matsumoto A.M., et al. Lack of seasonal variation in serum sex hormone levels in middle-aged to older men in the Boston area. J Clin Endocrinol Metab 2007, 92:4224-4229.
70. Martikainen H., Tapanainen J., Vakkuri O., et al. Circannual concentrations of melatonin, gonadotrophins, prolactin and gonadal steroids in males in a geographical area with a large annual variation in daylight. Acta Endocrinol 1985, 109:446-450.
71. Plymate S.R., Tenover J.S., Bremner W.J. Circadian variation in testosterone, sex hormone-binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men. J Androl 1989, 10:366-371.
72. Bremner W.J., Vitiello M.V., Prinz P.N. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983, 56:1278-1281.
73. Crawford E.D., Barqawi A.B., O'Donnell C., et al. The association of time of day and serum testosterone concentration in a large screening population. BJU Int 2007, 100:509-513.
74. Diver M.J., Imtiaz K.E., Ahmad A.M., et al. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol 2003, 58:710-717.
75. Axelsson J., Ingre M., Akerstedt T., et al. Effects of acutely displaced sleep on testosterone. J Clin Endocrinol Metab 2005, 90:4530-4535.
76. Rohrmann S., Nelson W.G., Rifai N., et al. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab 2007, 92:2519-2525.
77. Litman H.J., Bhasin S., Link C.L., et al. Serum androgen levels in black, Hispanic, and white men. J Clin Endocrinol Metab 2006, 91:4326-4334.
78. Wu A.H., Whittemore A.S., Kolonel L.N., et al. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev 1995, 4:735-741.
79. Harris J.A., Vernon P.A., Boomsma D.I. The heritability of testosterone: A study of Dutch adolescent twins and their parents. Behav Genet 1998, 28:165-171.
80. Hoekstra R.A., Bartels M., Boomsma D.I. Heritability of testosterone levels in 12-year-old twins and its relation to pubertal development. Twin Res Hum Genet 2006, 9:558-565.
81. Meikle A.W., Smith J.A., West D.W. Familial factors affecting prostatic cancer risk and plasma sex-steroid levels. Prostate 1985, 6:121-128.
82. Ahokoski O., Virtanen A., Huupponen R., et al. Biological day-to-day variation and daytime changes of testosterone, follitropin, lutropin and oestradiol-17beta in healthy men. Clin Chem Lab Med 1998, 36:485-491.
83. Valero-Politi J., Fuentes-Arderiu X. Within- and between-subject biological variations of follitropin, lutropin, testosterone, and sex-hormone-binding globulin in men. Clin Chem 1993, 39:1723-1725.
84. Lima N., Cavaliere H., Knobel M., et al. Decreased androgen levels in massively obese men may be associated with impaired function of the gonadostat. Int J Obes Relat Metab Disord 2000, 24:1433-1437.
85. Hammoud A., Gibson M., Hunt S.C., et al. Effect of Roux-en-Y gastric bypass surgery on the sex steroids and quality of life in obese men. J Clin Endocrinol Metab 2009, 94:1329-1332.
86. Nanjee M.N., Wheeler M.J. Plasma free testosterone-is an index sufficient?. Ann Clin Biochem 1985, 22:387-390.
87. Sodergard R., Backstrom T., Shanbhag V., et al. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 1982, 16:801-810.
88. Vermeulen A., Verdonck L., Kaufman J.M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999, 84:3666-3672.
89. Ly L.P., Handelsman D.J. Empirical estimation of free testosterone from testosterone and sex hormone-binding globulin immunoassays. Eur J Endocrinol 2005, 152:471-478.
90. Carvalho V.M. The coming of age of liquid chromatography coupled to tandem mass spectrometry in the endocrinology laboratory. J Chromatogr B 2012, 883-884:50-58.
91. Rosner W., Auchus R.J., Azziz R., et al. Position statement: Utility, limitations, and pitfalls in measuring testosterone: An Endocrine Society position statement. J Clin Endocrinol Metab 2007, 92:405-413.
92. Albrecht L., Styne D. Laboratory testing of gonadal steroids in children. Pediatr Endocrinol Rev 2007, 5(Suppl. 1):599-607.
93. Wierman M.E., Basson R., Davis S.R., et al. Androgen therapy in women: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2006, 91:3697-3710.
94. Vesper H.W., Miller W.G., Myers G.L. Reference materials and commutability. Clin Biochem Rev 2007, 28:139-147.
95. Vesper H.W., Botelho J.C. Standardization of testosterone measurements in humans. J Steroid Biochem Mol Biol 2010, 121:513-519.
96. Control CfD. Accessed May 12, 2016. http://www.cdc.gov/labstandards/hs.html.
97. Wang C., Nieschlag E., Swerdloff R., et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008, 159:507-514.
98. Bhasin S., Zhang A., Coviello A., et al. The impact of assay quality and reference ranges on clinical decision making in the diagnosis of androgen disorders. Steroids 2008, 73:1311-1317.
99. Dunn J.F., Nisula B.C., Rodbard D. Transport of steroid hormones: Binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 1981, 53:58-68.
100. Hammond G.L., Wu T.S., Simard M. Evolving utility of sex hormone-binding globulin measurements in clinical medicine. Curr Opin Endocrinol Diabetes Obes 2012, 19:183-189.
101. van den Beld A.W., de Jong F.H., Grobbee D.E., et al. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 2000, 85:3276-3282.
102. Almeida O.P., Yeap B.B., Hankey G.J., et al. Low free testosterone concentration as a potentially treatable cause of depressive symptoms in older men. Arch Gen Psychiatry 2008, 65:283-289.
103. Brand J.S., van der Tweel I., Grobbee D.E., et al. Testosterone, sex hormone-binding globulin and the metabolic syndrome: A systematic review and meta-analysis of observational studies. Int J Epidemiol 2011, 40:189-207.
104. Coviello A.D., Haring R., Wellons M., et al. A genome-wide association meta-analysis of circulating sex hormone-binding globulin reveals multiple loci implicated in sex steroid hormone regulation. PLoS Genet 2012, 8:e1002805.
105. Vanbillemont G., Bogaert V., De Bacquer D., et al. Polymorphisms of the SHBG gene contribute to the interindividual variation of sex steroid hormone blood levels in young, middle-aged and elderly men. Clin Endocrinol 2009, 70:303-310.
106. Hammes A., Andreassen T.K., Spoelgen R., et al. Role of endocytosis in cellular uptake of sex steroids. Cell 2005, 122:751-762.
107. Morris P.D., Malkin C.J., Channer K.S., et al. A mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men. Eur J Endocrinol 2004, 151:241-249.
108. Zakharov M.N., Bhasin S., Travison T.G., et al. A multi-step, dynamic allosteric model of testosterone's binding to sex hormone binding globulin. Mol Cell Endocrinol 2015, 399:190-200.
109. Heinemann L.A., Zimmermann T., Vermeulen A., et al. A new 'Aging Male's Symptom' rating scale. Aging Male 1999, 2:105-114.
110. Morley J.E., Charlton E., Patrick P., et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000, 49:1239-1242.
111. Smith K.W., Feldman H.A., McKinlay J.B. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol 2000, 53:703-711.
112. Wiltink J., Beutel M.E., Brahler E., et al. Hypogonadism-related symptoms: Development and evaluation of an empirically derived self-rating instrument (HRS 'Hypogonadism Related Symptom Scale'). Andrologia 2009, 41:297-304.
113. McMillan C.V., Bradley C., Giannoulis M., et al. Preliminary development of a new individualised questionnaire measuring quality of life in older men with age-related hormonal decline: The A-RHDQoL. Health Qual Life Outcomes 2003, 1:51.
114. Corona G., Mannucci E., Petrone L., et al. ANDROTEST: A structured interview for the screening of hypogonadism in patients with sexual dysfunction. J Sex Med 2006, 3:706-715.
115. Morley J.E., Perry H.M., Kevorkian R.T., et al. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas 2006, 53:424-429.
116. Blumel J.E., Chedraui P., Gili S.A., et al. Is the Androgen Deficiency of Aging Men (ADAM) questionnaire useful for the screening of partial androgenic deficiency of aging men?. Maturitas 2009, 63:365-368.
117. Tancredi A., Reginster J.Y., Schleich F., et al. Interest of the Androgen Deficiency in Aging Males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers. Eur J Endocrinol 2004, 151:355-360.
118. Spetz A.C., Palmefors L., Skobe R.S., et al. Testosterone correlated to symptoms of partial androgen deficiency in aging men (PADAM) in an elderly Swedish population. Menopause 2007, 14:999-1005.
119. Emmelot-Vonk M.H., Verhaar H.J., Nakhai-Pour H.R., et al. Low testosterone concentrations and the symptoms of testosterone deficiency according to the Androgen Deficiency in Ageing Males (ADAM) and Ageing Males' Symptoms rating scale (AMS) questionnaires. Clin Endocrinol 2011, 74:488-494.
120. Heinemann L.A., Saad F., Heinemann K., et al. Can results of the Aging Males' Symptoms (AMS) scale predict those of screening scales for androgen deficiency?. Aging Male 2004, 7:211-218.
121. Ho C.C., Tong S.F., Low W.Y., et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU Int 2012, 110:260-265.
122. Medicine CfEB. Oxford Centre for Evidence-based Medicine - Levels of Evidence 2009. Accessed May 12, 2016. http://www.cebm.net/index.aspx?o=1025.
123. Shores M.M., Smith N.L., Forsberg C.W., et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012, 97:2050-2058.
124. Fernandez-Balsells M.M., Murad M.H., Lane M., et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: A systematic review and meta-analysis. J Clin Endocrinol Metab 2010, 95:2560-2575.
125. Leder B.Z., Finkelstein J.S. Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. Osteoporos Int 2005, 16:1487-1494.
126. Burnett-Bowie S.A., McKay E.A., Lee H., et al. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab 2009, 94:4785-4792.
127. Aversa A., Bruzziches R., Francomano D., et al. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: Results from a 36 months controlled study. Aging Male 2012, 15:96-102.
128. Tenover J.S., Bremner W.J. The effects of normal aging on the response of the pituitary-gonadal axis to chronic clomiphene administration in men. J Androl 1991, 12:258-263.
129. Vigen R., O'Donnell C.I., Baron A.E., et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013, 310:1829-1836.
130. Finkelstein J.S., Lee H., Burnett-Bowie S.A., et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med 2013, 369:1011-1022.
131. Snyder P.J., Peachey H., Hannoush P., et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999, 84:1966-1972.
132. Corona G., Isidori A.M., Buvat J., et al. Testosterone supplementation and sexual function: A meta-analysis study. J Sex Med 2014, 11:1577-1592.
133. Antonio L, Wu FC, O'Neill TW, et al. Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone. J Clin Endocrinol Metab. E-pub ahead of print. doi:10.1210/jc.2015-4106.
134. Zarrouf F.A., Artz S., Griffith J., et al. Testosterone and depression: Systematic review and meta-analysis. J Psychiatr Pract 2009, 15:289-305.
135. Moskovic D.J., Katz D.J., Akhavan A., et al. Clomiphene citrate is safe and effective for long-term management of hypogonadism. BJU Int 2012, 110:1524-1528.
136. Ip F.F., di Pierro I., Brown R., et al. Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets. Eur J Endocrinol 2010, 162:385-390.
137. Vorkas C.K., Vaamonde C.M., Glesby M.J. Testosterone replacement therapy and polycythemia in HIV-infected patients. AIDS 2012, 26:243-245.
138. Kaufman J.M., Miller M.G., Garwin J.L., et al. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. J Sex Med 2011, 8:2079-2089.
139. Mazer N., Bell D., Wu J., et al. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men. J Sex Med 2005, 2:213-226.
140. Jadad A.R., Cook D.J., Jones A., et al. Methodology and reports of systematic reviews and meta-analyses: A comparison of Cochrane reviews with articles published in paper-based journals. JAMA 1998, 280:278-280.
141. Rosen R.C., Allen K.R., Ni X., et al. Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. Eur Urol 2011, 60:1010-1016.
142. Calof O.M., Singh A.B., Lee M.L., et al. Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005, 60:1451-1457.
143. Kaplan A.L., Hu J.C. Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes. Urology 2013, 82:321-326.
144. Pastuszak A.W., Pearlman A.M., Lai W.S., et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol 2013, 190:639-644.